Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial
Checkpoint immunotherapy is a promising treatment option for advanced cervical cancer. To aid in selecting patients for this treatment, we identified potential predictors of the response to anti-PD-1 combination therapy. We simultaneously characterized CD8 CD8 Multiparametric immune profiling of CD8 ClinicalTrials. gov identifier: NCT03816553, January 25, 2019.